کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4209562 | 1280490 | 2008 | 6 صفحه PDF | دانلود رایگان |
In this study we examined pharmacokinetics, systemic exposure and sputum penetration of azithromycin (AZM) in CF patients on chronic daily AZM therapy after changing to a once weekly dosing scheme.Eight adult CF patients using AZM 500 mg/day were changed to a once weekly dose of 1000 mg during 3 months. Once per month sputum and blood samples were collected. AZM was quantified in blood plasma and polymorphonuclear neutrophils.The cumulative weekly dose was reduced with a factor of 3.5 (7 × 500 mg vs. 1 × 1000 mg weekly).This led to a reduction in area under the curve (AUC ± S.D.) with a factor of 2.5 ± 0.8 in plasma, 2.8 ± 0.9 in blood, 2.2 ± 1.1 in PMNNs and to a reduction in average sputum concentration with a factor of 3.0 (± 1.5).At 1000 mg once weekly reduced but still substantial concentrations were achieved in PMNNs and in sputum. Although not significant, a tendency towards less than linear reduction was found. In order to calculate and propose an optimal dosing scheme we need to establish a relation between exposure levels and clinical efficacy.
Journal: Journal of Cystic Fibrosis - Volume 7, Issue 1, January 2008, Pages 79–84